BR0308576A - Compostos: composições farmacêuticas para administração em um mamìfero e métodos para inibir a enzima citocroma p450rai em um mamìfero - Google Patents

Compostos: composições farmacêuticas para administração em um mamìfero e métodos para inibir a enzima citocroma p450rai em um mamìfero

Info

Publication number
BR0308576A
BR0308576A BR0308576-7A BR0308576A BR0308576A BR 0308576 A BR0308576 A BR 0308576A BR 0308576 A BR0308576 A BR 0308576A BR 0308576 A BR0308576 A BR 0308576A
Authority
BR
Brazil
Prior art keywords
mammal
compounds
inhibiting
administration
methods
Prior art date
Application number
BR0308576-7A
Other languages
English (en)
Inventor
Jayasree Vasudevan
Liming Wang
Xiaoxia Liu
Kwok-Yin Tsang
Yang-Dar Yuan
Roshantha A Chandraratna
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR0308576A publication Critical patent/BR0308576A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)

Abstract

"COMPOSTOS; COMPOSIçõES FARMACêUTICAS PARA ADMINISTRAçãO EM UM MAMìFERO E MéTODOS PARA INIBIR A ENZIMA CITOCROMA P450RAI EM UM MAMìFERO". Descreve-se compostos da fórmula (I) nos quais as variáveis estão definidas no relatório descritivo, que têm atividade inibitória de citocroma P450RAI-1 e P450RAI-2, e são apropriados para o tratamento de mamíferos portadores de condições tratáveis com retinóides, ou que são controladas por ou responsivas ao ácido retinóico nativo do organismo. As formulações que contêm os compostos da invenção podem ser administradas também com retinóides e/ou vitamina A, para intensificar ou prolongar os efeitos de medicações que contêm retinóides, vitamina A, ou o ácido retinóico nativo do organismo.
BR0308576-7A 2002-03-19 2003-03-11 Compostos: composições farmacêuticas para administração em um mamìfero e métodos para inibir a enzima citocroma p450rai em um mamìfero BR0308576A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/100,638 US6740676B2 (en) 2002-03-19 2002-03-19 4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome p450rai inhibitory activity
PCT/US2003/007612 WO2003080594A1 (en) 2002-03-19 2003-03-11 Substituted chroman derivatives having cytochrome p450rai inhibitory activity

Publications (1)

Publication Number Publication Date
BR0308576A true BR0308576A (pt) 2005-01-04

Family

ID=28452321

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308576-7A BR0308576A (pt) 2002-03-19 2003-03-11 Compostos: composições farmacêuticas para administração em um mamìfero e métodos para inibir a enzima citocroma p450rai em um mamìfero

Country Status (12)

Country Link
US (2) US6740676B2 (pt)
EP (1) EP1485368A1 (pt)
JP (1) JP2005525387A (pt)
CN (1) CN1656088A (pt)
AR (1) AR039027A1 (pt)
AU (1) AU2003213848B2 (pt)
BR (1) BR0308576A (pt)
CA (1) CA2478913A1 (pt)
IL (1) IL164103A0 (pt)
MX (1) MXPA04009046A (pt)
TW (1) TW200305399A (pt)
WO (1) WO2003080594A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6740676B2 (en) * 2002-03-19 2004-05-25 Allergan, Inc. 4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome p450rai inhibitory activity
US20040077721A1 (en) * 2002-03-19 2004-04-22 Yang-Dar Yuan Compositions and methods using compounds having cytochrome P450RAI inhibitory activity co-administered with vitamin A
JP2009221164A (ja) * 2008-03-17 2009-10-01 Nitto Denko Corp 肺線維症処置剤
WO2006068232A1 (ja) 2004-12-22 2006-06-29 Sapporo Medical University 線維化抑制のための薬物担体および薬物担体キット
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
KR100801029B1 (ko) 2005-12-27 2008-02-04 제일모직주식회사 디아민 화합물 및 이를 이용한 액정 배향제
US20070185055A1 (en) * 2006-02-06 2007-08-09 Guang Liang Jiang Method for treating cachexia with retinoid ligands
TWI407971B (zh) 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
CN101965186A (zh) * 2007-11-28 2011-02-02 塞阔伊亚药品公司 抑制细胞色素p450 2d6的化合物和方法
CN111233809B (zh) * 2020-01-16 2021-12-03 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 一种Millepachine-CA-4衍生物及其制备方法和应用
WO2023190164A1 (ja) * 2022-03-28 2023-10-05 日油株式会社 アリールエステルを含むカルボン酸の製造方法及びカチオン性脂質の製造方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH651034A5 (de) 1982-05-12 1985-08-30 Hoffmann La Roche Chroman-, thiochroman- oder 1,2,3,4-tetrahydrochinolinderivate und ihre verwendung als arzneimittel-wirkstoffe.
ATE38835T1 (de) 1983-07-05 1988-12-15 Pfizer Karbonsaeure-derivate verwendbar bei der verhuetung der zersetzung von knorpeln.
WO1985000806A1 (en) 1983-08-08 1985-02-28 Sri International Benzonorbornenyl, benzopyranyl and benzothiopyranyl retinoic acid analogues
US4658065A (en) * 1984-03-28 1987-04-14 Asahi Kasei Kogyo Kabushiki Kaisha Process for producing polyether polyol and a product
US4826984A (en) 1984-04-09 1989-05-02 The Board Of Regents For The Oklahoma Agricultural And Mechanical College Acting For And On Behalf Of Oklahoma State University Heteroarotinoid compounds as anticancer agents
LU86351A1 (fr) 1986-03-12 1987-11-11 Oreal Composes benzopyrannyl et benzothiopyrannyl benzoiques,leur procede de preparation et leur utilisation en cosmetique et en medecine humaine et veterinaire
US5149705A (en) 1987-03-13 1992-09-22 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a tetralin group and having retinoid like activity
US5264578A (en) 1987-03-20 1993-11-23 Allergan, Inc. Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity
US5089509A (en) 1988-09-15 1992-02-18 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
AU626881B2 (en) 1988-07-14 1992-08-13 F. Hoffmann-La Roche Ag Benzofused heterocyclics used as pharmaceuticals
US5399561A (en) 1989-09-19 1995-03-21 Allergan, Inc. Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-oxochromanyl, 2-oxothiochromanyl or 2-oxo-1,2,3,4-tetrahydro-quinolinyl group having retinoid-like biological activity
US4980369A (en) 1989-09-19 1990-12-25 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl or thiochromanyl group having retinoid-like activity
US5023341A (en) 1989-09-19 1991-06-11 Allergan, Inc. Compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity
US5045551A (en) 1989-09-19 1991-09-03 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5006550A (en) * 1989-12-29 1991-04-09 Allergan, Inc. Chroman esters of phenols and benzoic acids having retinoid-like activity
AU652189B2 (en) * 1990-10-09 1994-08-18 Allergan, Inc. Chromans and thiochromans with retinoid-like activity
DE69214632T2 (de) 1991-02-13 1997-05-28 Allergan Inc 7-phenylethynyl-substituierte chromane und thiochromane mit retinoid-ähnlicher biologischer aktivität
US5134159A (en) 1991-03-26 1992-07-28 Allergan, Inc. 7-chromanyl esters of phenols and benzoic acids having retinoid-like activity
EP0577737A1 (en) 1991-03-26 1994-01-12 Allergan, Inc. Chromans and thiochromans with heteroarylethynyl substituents at the 7-position having retinoid-like biological activity
EP0617614B1 (en) 1991-12-18 1998-03-04 The Salk Institute For Biological Studies Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
US5466861A (en) 1992-11-25 1995-11-14 Sri International Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
CA2153236A1 (en) 1993-01-11 1995-02-09 Marcus F. Boehm Compounds having selective activity for retinoid x receptors, and means for modulation of processes mediated by retinoid x receptors
US5455265A (en) 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
US5675024A (en) * 1995-11-22 1997-10-07 Allergan Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
US5965606A (en) 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
KR20030005202A (ko) * 2000-02-21 2003-01-17 다케다 야쿠힌 고교 가부시키가이샤 환상 화합물의 제조 방법
CZ20024220A3 (cs) * 2000-06-30 2003-06-18 Unilever N. V. Prostředek pro péči o pleť
DE60116642T2 (de) * 2000-08-29 2006-11-09 Allergan, Inc., Irvine Verbindungen mit cytochrom p450ra1 hemmenden aktivität
US6303785B1 (en) 2000-08-29 2001-10-16 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6313107B1 (en) 2000-08-29 2001-11-06 Allergan Sales, Inc. Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
US6252090B1 (en) * 2000-08-29 2001-06-26 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6740676B2 (en) * 2002-03-19 2004-05-25 Allergan, Inc. 4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome p450rai inhibitory activity
US20040077721A1 (en) * 2002-03-19 2004-04-22 Yang-Dar Yuan Compositions and methods using compounds having cytochrome P450RAI inhibitory activity co-administered with vitamin A

Also Published As

Publication number Publication date
US7351737B2 (en) 2008-04-01
CA2478913A1 (en) 2003-10-02
AU2003213848B2 (en) 2007-08-16
TW200305399A (en) 2003-11-01
CN1656088A (zh) 2005-08-17
US20030207937A1 (en) 2003-11-06
IL164103A0 (en) 2005-12-18
MXPA04009046A (es) 2005-06-08
US6740676B2 (en) 2004-05-25
EP1485368A1 (en) 2004-12-15
WO2003080594A1 (en) 2003-10-02
AU2003213848A1 (en) 2003-10-08
AR039027A1 (es) 2005-02-02
JP2005525387A (ja) 2005-08-25
US20030191181A1 (en) 2003-10-09

Similar Documents

Publication Publication Date Title
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
BR0314943A (pt) Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes
BRPI0408999A (pt) comprimidos prensados de multiparticulados de liberação oral prolongada
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
ECSP056182A (es) Derivados de carbostirilo y estabilizantes del estado de ánimo para tratar trastornos del mismo
SE0001899D0 (sv) New compounds
BR0109336A (pt) Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico
CA2238465A1 (fr) Composes triaromatiques, compositions les contenant et utilisations
BRPI0515483A (pt) derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
BRPI0409314A (pt) derivados de 2-aminopirimidina e seu uso médico
BR0308576A (pt) Compostos: composições farmacêuticas para administração em um mamìfero e métodos para inibir a enzima citocroma p450rai em um mamìfero
CA2396186A1 (en) Agents for the treatment of skin disorders
KR900017590A (ko) 좌창(Acne)치료방법 및 그 약제 조성물
CA2392165A1 (fr) Analogues de la vitamine d
BR9713921A (pt) Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa
CA2218766A1 (fr) Composes bicycliques-aromatiques
MD1688G2 (ro) Benzotiofen, benzofuran şi indoltiazepinone, oxazepinone şi diazepinone, compoziţie farmaceutică, metodă de inhibare a aderării leucocitelor la celulele endoteliale pentru tratamentul proceselor inflamatorii şi metodă de tratament al mamiferelor infectate cu HIV infecţie .
BR0215277A (pt) Dicetopiperazinas substituìdas como antagonistas da oxitocina
BRPI0408882A (pt) composições contendo lactulose para tratamento de infecções por rotavìrus
BR0316261A (pt) Composto, composição farmacêutica que compreende o mesmo, método para tratar uma enfermidade caracterizada por renovação, ativação, ou renovação e ativação de leucócitos patogênicos e método de antagonização de um receptor de quimioquinas c-c 1 em um paciente
MX9501849A (es) Nuevos compuestos biciclicos-aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y sus usos.
SE9903894D0 (sv) Novel compounds
BRPI0410654A (pt) composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto
CA2305933A1 (fr) Composes (poly)thia-alcynoiques et leurs derives, compositions les comprenant et leur utilisation

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A,8A E 9A ANUIDADE(S).

B08G Application fees: restoration [chapter 8.7 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]